Linked Life Data

17701580

Source:http://linkedlifedata.com/resource/pubmed/id/17701580

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17701580rdf:typepubmed:Citationlld:pubmed
pubmed-article:17701580lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:17701580lifeskim:mentionsumls-concept:C0376622lld:lifeskim
pubmed-article:17701580lifeskim:mentionsumls-concept:C1332002lld:lifeskim
pubmed-article:17701580lifeskim:mentionsumls-concept:C1704939lld:lifeskim
pubmed-article:17701580lifeskim:mentionsumls-concept:C0334634lld:lifeskim
pubmed-article:17701580lifeskim:mentionsumls-concept:C1550594lld:lifeskim
pubmed-article:17701580lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:17701580lifeskim:mentionsumls-concept:C1336767lld:lifeskim
pubmed-article:17701580lifeskim:mentionsumls-concept:C1823242lld:lifeskim
pubmed-article:17701580lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:17701580lifeskim:mentionsumls-concept:C0040808lld:lifeskim
pubmed-article:17701580lifeskim:mentionsumls-concept:C1548760lld:lifeskim
pubmed-article:17701580lifeskim:mentionsumls-concept:C1547300lld:lifeskim
pubmed-article:17701580lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:17701580lifeskim:mentionsumls-concept:C0392760lld:lifeskim
pubmed-article:17701580lifeskim:mentionsumls-concept:C0580822lld:lifeskim
pubmed-article:17701580pubmed:issue8lld:pubmed
pubmed-article:17701580pubmed:dateCreated2007-8-16lld:pubmed
pubmed-article:17701580pubmed:abstractTextThe genomic profile of mantle cell lymphoma (MCL) has been reported to be significantly different from that of other indolent lymphoproliferative disorders, Topoisomerase IIalpha, glutathione-s-transferasepi (GSTpi) and ABCG2 (BCRP) chemoresistance genes being over-expressed in MCL. In our study, expression levels of the above mentioned genes plus MDR1 were tested on bone marrow samples from 20 patients treated with Rituximab plus hyper-CVAD regimen, in order to evaluate a possible impact of the chemoresistance phenomenon on this promising treatment regimen. All patients expressed ABCG2 and MDR1 genes; 85% of cases expressed GSTpi and topoisomerase IIalpha. Only ABCG2 were over-expressed in comparison both with marrow from healthy donors and tonsilar CD5+/CD20+ lymphocytes (adopted as normal counterpart of the neoplastic population). The overall response rate of the entire series was 87.5%, with 44% of complete responses. Fifty-seven percent of patients achieved the clearance of minimal residual disease. Levels of tested genes did not condition either quality of clinical response or PFS (76% at 24 months). Nevertheless, an ABCG2 higher expression appeared associated with a worse PFS and levels of this gene paralleled the status of minimal residual disease. A further evaluation of ABCG2 expression in larger series of MCL patients would be suitable.lld:pubmed
pubmed-article:17701580pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17701580pubmed:languageenglld:pubmed
pubmed-article:17701580pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17701580pubmed:citationSubsetIMlld:pubmed
pubmed-article:17701580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17701580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17701580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17701580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17701580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17701580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17701580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17701580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17701580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17701580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17701580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17701580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17701580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17701580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17701580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17701580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17701580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17701580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17701580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17701580pubmed:statusMEDLINElld:pubmed
pubmed-article:17701580pubmed:monthAuglld:pubmed
pubmed-article:17701580pubmed:issn1042-8194lld:pubmed
pubmed-article:17701580pubmed:authorpubmed-author:FazziRitaRlld:pubmed
pubmed-article:17701580pubmed:authorpubmed-author:GalimbertiSar...lld:pubmed
pubmed-article:17701580pubmed:authorpubmed-author:PetriniMarioMlld:pubmed
pubmed-article:17701580pubmed:authorpubmed-author:PaciniSimoneSlld:pubmed
pubmed-article:17701580pubmed:authorpubmed-author:NagyBalintBlld:pubmed
pubmed-article:17701580pubmed:authorpubmed-author:GuerriniFranc...lld:pubmed
pubmed-article:17701580pubmed:authorpubmed-author:BenedettiEdoa...lld:pubmed
pubmed-article:17701580pubmed:authorpubmed-author:CaraccioloFra...lld:pubmed
pubmed-article:17701580pubmed:authorpubmed-author:PapineschiFed...lld:pubmed
pubmed-article:17701580pubmed:authorpubmed-author:BrizziStefani...lld:pubmed
pubmed-article:17701580pubmed:authorpubmed-author:CiabattiElena...lld:pubmed
pubmed-article:17701580pubmed:authorpubmed-author:CanestraroMar...lld:pubmed
pubmed-article:17701580pubmed:issnTypePrintlld:pubmed
pubmed-article:17701580pubmed:volume48lld:pubmed
pubmed-article:17701580pubmed:ownerNLMlld:pubmed
pubmed-article:17701580pubmed:authorsCompleteYlld:pubmed
pubmed-article:17701580pubmed:pagination1502-9lld:pubmed
pubmed-article:17701580pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:meshHeadingpubmed-meshheading:17701580...lld:pubmed
pubmed-article:17701580pubmed:year2007lld:pubmed
pubmed-article:17701580pubmed:articleTitleEvaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen.lld:pubmed
pubmed-article:17701580pubmed:affiliationDepartment of Oncology, Transplants and Advances in Medicine, Hematology Section, University of Pisa, Italy. s.galimberti@med.unipi.itlld:pubmed
pubmed-article:17701580pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17701580pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:17701580pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
entrez-gene:9429entrezgene:pubmedpubmed-article:17701580lld:entrezgene
lhgdn:association:2513lhgdn:found_inpubmed-article:17701580lld:lhgdn
lhgdn:association:2521lhgdn:found_inpubmed-article:17701580lld:lhgdn
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17701580lld:pubmed
More...